DK3482767T3 - Dosisoptrapningsenzymerstatningsterapi til behandling af mangel på sur sphingomyelinase - Google Patents

Dosisoptrapningsenzymerstatningsterapi til behandling af mangel på sur sphingomyelinase Download PDF

Info

Publication number
DK3482767T3
DK3482767T3 DK18199358.5T DK18199358T DK3482767T3 DK 3482767 T3 DK3482767 T3 DK 3482767T3 DK 18199358 T DK18199358 T DK 18199358T DK 3482767 T3 DK3482767 T3 DK 3482767T3
Authority
DK
Denmark
Prior art keywords
enzymer
substitute
dosage
reception
acid sphingomyelinase
Prior art date
Application number
DK18199358.5T
Other languages
English (en)
Inventor
Edward H Schuchman
Robert J Desnick
Gerald F Cox
Laura P Andrews
James M Murray
Original Assignee
Icahn School Med Mount Sinai
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3482767(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icahn School Med Mount Sinai, Genzyme Corp filed Critical Icahn School Med Mount Sinai
Application granted granted Critical
Publication of DK3482767T3 publication Critical patent/DK3482767T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)
DK18199358.5T 2009-08-28 2010-08-28 Dosisoptrapningsenzymerstatningsterapi til behandling af mangel på sur sphingomyelinase DK3482767T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28
EP10812683.0A EP2470199B1 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Publications (1)

Publication Number Publication Date
DK3482767T3 true DK3482767T3 (da) 2021-12-20

Family

ID=43625265

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18199358.5T DK3482767T3 (da) 2009-08-28 2010-08-28 Dosisoptrapningsenzymerstatningsterapi til behandling af mangel på sur sphingomyelinase
DK10812683.0T DK2470199T3 (da) 2009-08-28 2010-08-28 Dosisoptrapning enzymerstatningsterapi til behandling af mangel på sur sphingomyelinase

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10812683.0T DK2470199T3 (da) 2009-08-28 2010-08-28 Dosisoptrapning enzymerstatningsterapi til behandling af mangel på sur sphingomyelinase

Country Status (26)

Country Link
US (9) US8349319B2 (da)
EP (3) EP3482767B1 (da)
JP (7) JP5955219B2 (da)
KR (5) KR102608546B1 (da)
CN (3) CN102596232A (da)
AU (5) AU2010286550B2 (da)
BR (1) BR112012004377A2 (da)
CA (1) CA2773133A1 (da)
CL (1) CL2012000495A1 (da)
CY (1) CY1122128T1 (da)
DK (2) DK3482767T3 (da)
ES (2) ES2902229T3 (da)
FR (1) FR22C1062I2 (da)
HR (2) HRP20211992T1 (da)
HU (3) HUE057440T2 (da)
IL (3) IL300625A (da)
LT (2) LT3482767T (da)
MX (1) MX356873B (da)
NL (1) NL301211I2 (da)
PL (2) PL2470199T3 (da)
PT (2) PT2470199T (da)
RU (3) RU2731616C2 (da)
SI (2) SI2470199T1 (da)
TR (1) TR201911293T4 (da)
WO (1) WO2011025996A2 (da)
ZA (2) ZA201201435B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
EP3252161B1 (en) 2007-06-06 2021-11-17 Genzyme Corporation Gene therapy for lysosomal storage diseases
DK3482767T3 (da) * 2009-08-28 2021-12-20 Icahn School Med Mount Sinai Dosisoptrapningsenzymerstatningsterapi til behandling af mangel på sur sphingomyelinase
US8882701B2 (en) 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
JP2013528379A (ja) 2010-05-21 2013-07-11 オームクス コーポレーション Ｐｓａ酵素活性アッセイによる癌の検出
UA118248C2 (uk) 2011-03-18 2018-12-26 Джензім Корпорейшн Інгібітори глюкозилцерамідсинтази
SI2753346T1 (sl) 2011-09-07 2020-09-30 Mount Sinai School Of Medicine Ceramidaza in diferenciacija celic
DK2780716T3 (da) 2011-11-15 2019-10-14 Centogene Ag Fremgangsmåde til diagnose af Niemann-Pick sygdom
ES2897825T3 (es) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
EP2968479B1 (en) * 2013-03-14 2019-07-17 Icahn School of Medicine at Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
US10302664B2 (en) * 2013-05-14 2019-05-28 Centogene Ag Method for the diagnosis of Niemann-Pick disease
LT3004896T (lt) 2013-06-07 2020-01-10 Genzyme Corporation Rūgštinės sfingomielinazės sutrikimų žymuo ir jo panaudojimas
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
KR20200044064A (ko) * 2017-08-24 2020-04-28 사노피 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
UY38238A (es) 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
ES2326705T3 (es) 1995-09-14 2009-10-16 Virginia Tech Intellectual Properties, Inc. Produccion de enzimas lisosomicas en sistemas de expresion basados en plantas.
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
WO2000037610A2 (en) 1998-12-23 2000-06-29 Boyce Thompson Institute For Plant Research At Cornell Expression of immunogenic hepatitis b surface antigens in transgenic plants
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2001286636A1 (en) 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
EP1639085A2 (en) 2003-06-12 2006-03-29 Genzyme Corporation Modified human acid sphingomyelinase having increased activity, and methods for making the same
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005051331A2 (en) 2003-11-25 2005-06-09 Mount Sinai School Of Medicine Of New York University Chaperone-based therapy for niemann-pick disease
MX2007004414A (es) 2004-10-13 2007-09-25 Protalix Ltd Sistema y metodo para la produccion de anticuerpos en cultivos de celulas de plantas.
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
JP2009519713A (ja) 2005-12-15 2009-05-21 ザ リサーチ ファウンデーション オブ ステート ユニバーシティ オブ ニューヨーク 血漿中及び組織中のスフィンゴエミリン及びホスファチジルコリンの酵素的測定方法
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US10265412B2 (en) 2006-02-06 2019-04-23 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
CA3168881A1 (en) * 2006-02-09 2007-08-23 Genzyme Corporation Slow intraventricular delivery
KR20080106433A (ko) 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
JP5302189B2 (ja) 2007-04-27 2013-10-02 長瀬産業株式会社 スフィンゴミエリナーゼ
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
US8835614B2 (en) 2008-12-16 2014-09-16 Genzyme Corporation Oligosaccharide-protein conjugates
DK3482767T3 (da) * 2009-08-28 2021-12-20 Icahn School Med Mount Sinai Dosisoptrapningsenzymerstatningsterapi til behandling af mangel på sur sphingomyelinase
EP2721151B1 (en) * 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders

Also Published As

Publication number Publication date
IL218324A0 (en) 2012-04-30
AU2020256322B2 (en) 2024-02-29
LT3482767T (lt) 2022-01-10
IL266915A (en) 2019-07-31
AU2010286550B2 (en) 2016-05-19
FR22C1062I1 (fr) 2023-02-03
NL301211I2 (nl) 2023-02-02
CY1122128T1 (el) 2020-11-25
IL266915B1 (en) 2023-03-01
JP6251307B2 (ja) 2017-12-20
CA2773133A1 (en) 2011-03-03
US20110052559A1 (en) 2011-03-03
FR22C1062I2 (fr) 2023-12-29
US20180055916A1 (en) 2018-03-01
IL266915B2 (en) 2023-07-01
SI2470199T1 (sl) 2019-11-29
AU2010286550A1 (en) 2012-03-15
PL2470199T3 (pl) 2019-11-29
NL301211I1 (nl) 2022-12-28
HUS2200050I1 (hu) 2022-12-28
AU2020256322A1 (en) 2020-11-12
KR20220104271A (ko) 2022-07-26
JP7167281B2 (ja) 2022-11-08
JP7395693B2 (ja) 2023-12-11
JP2024026214A (ja) 2024-02-28
ES2902229T3 (es) 2022-03-25
RU2731616C2 (ru) 2020-09-07
ZA201601362B (en) 2017-05-31
KR20120081077A (ko) 2012-07-18
KR20200034828A (ko) 2020-03-31
US20130078231A1 (en) 2013-03-28
HRP20191385T1 (hr) 2019-11-01
JP2013502933A (ja) 2013-01-31
KR102094253B1 (ko) 2020-03-31
WO2011025996A2 (en) 2011-03-03
LT2470199T (lt) 2019-10-10
US9114139B2 (en) 2015-08-25
BR112012004377A2 (pt) 2017-12-12
EP2470199A2 (en) 2012-07-04
RU2012111823A (ru) 2013-10-10
KR102608551B1 (ko) 2023-12-04
EP3482767B1 (en) 2021-10-06
US8658162B2 (en) 2014-02-25
AU2018204156A1 (en) 2018-06-28
JP5955219B2 (ja) 2016-07-20
US20130078230A1 (en) 2013-03-28
TR201911293T4 (tr) 2019-08-21
RU2020128994A (ru) 2022-03-02
HUE057440T2 (hu) 2022-05-28
US20220305091A1 (en) 2022-09-29
PT2470199T (pt) 2019-08-07
US8349319B2 (en) 2013-01-08
AU2016216625B2 (en) 2018-07-05
KR102608546B1 (ko) 2023-12-04
MX2012002449A (es) 2012-03-14
US20210077593A1 (en) 2021-03-18
AU2024201085A1 (en) 2024-03-07
AU2016216625A1 (en) 2016-09-15
US9655954B2 (en) 2017-05-23
US20190151419A1 (en) 2019-05-23
US10188705B2 (en) 2019-01-29
AU2018204156B2 (en) 2020-07-16
JP2022003065A (ja) 2022-01-11
US20140335070A1 (en) 2014-11-13
CL2012000495A1 (es) 2014-02-07
EP2470199A4 (en) 2013-03-27
JP6952810B2 (ja) 2021-10-20
JP2016153408A (ja) 2016-08-25
HRP20211992T1 (hr) 2022-04-01
US8709408B2 (en) 2014-04-29
PT3482767T (pt) 2021-12-29
JP2020090513A (ja) 2020-06-11
RU2569744C2 (ru) 2015-11-27
US20160120957A1 (en) 2016-05-05
MX356873B (es) 2018-06-18
WO2011025996A3 (en) 2012-03-15
CN102596232A (zh) 2012-07-18
IL300625A (en) 2023-04-01
ES2738859T3 (es) 2020-01-27
RU2015145255A3 (da) 2019-08-12
CN105999238A (zh) 2016-10-12
WO2011025996A9 (en) 2011-08-25
IL218324B (en) 2019-05-30
JP2018076322A (ja) 2018-05-17
DK2470199T3 (da) 2019-08-05
KR20210107153A (ko) 2021-08-31
KR20230164773A (ko) 2023-12-04
SI3482767T1 (sl) 2022-03-31
JP2023012499A (ja) 2023-01-25
EP3482767A1 (en) 2019-05-15
EP3998078A1 (en) 2022-05-18
RU2015145255A (ru) 2019-01-11
HUE046598T2 (hu) 2020-03-30
ZA201201435B (en) 2020-05-27
EP2470199B1 (en) 2019-05-22
CN106047835A (zh) 2016-10-26
PL3482767T3 (pl) 2022-02-14

Similar Documents

Publication Publication Date Title
DK3482767T3 (da) Dosisoptrapningsenzymerstatningsterapi til behandling af mangel på sur sphingomyelinase
DK2411028T3 (da) Terapi til fremme af cellevækst
DK2442791T3 (da) Former til dosering af apixaban
BRPI1009197A2 (pt) preparação de ácido alfa-cetopimélico
SG10201401145YA (en) Ribbed water spike
LT2501413T (lt) Polimero-vaisto konjugato rūgšties druskų formos
HK1183258A1 (zh) 內聯分水器
DK2332510T3 (da) Forbindelsesorgan
AP3665A (en) Water treatment
DK2453858T3 (da) Fremgangsmåde
FI20105919A0 (fi) Menetelmä veden puhdistamiseksi
BRPI1006968A2 (pt) microbiocidas
DK2430285T3 (da) Undervandsspil
DK2279940T3 (da) Forbindelsesindretning til flapror til vandbefordringsmidler
PL2390431T3 (pl) Odpływ rynienkowy
DE102009039454A8 (de) Isolierschlauch
DK2262062T3 (da) Connector
TH115366B (th) รูปแบบขนาดยาของแข็ง
TH104643B (th) เหยือกน้ำ
TH126348B (th) สารผสม
DE102009038999A8 (de) Wassernachfüllstopfen
FIU20090248U0 (fi) Eristyselementti
GB201000385D0 (en) Photovoltaic decking solution
FI8665U1 (fi) Tasorakenne
FI20096074A0 (fi) Liitosväline